BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 18, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cardene I: Interim Phase IV data

Interim data from an open-label, U.S. Phase IV trial in 47 patients showed that a significantly greater proportion of patients receiving Cardene I.V. achieved their target blood pressure by 24 hours vs. IV labetalol (100% vs. 68%, p<0.001). Additionally, a significantly greater proportion of...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >